Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor

• Published in: Radiología (English ed.) Vol. 58; no. 4; pp. 283 - 293
• Main Authors: Sebastián Sebastián, C, García Mur, C, Cruz Ciria, S, Rosero Cuesta, D.S, Gros Bañeres, B
• Format: Journal Article
• Language: English
• Published: Elsevier España, S.L.U 01.07.2016
• Subjects: Breast cancer; Carcinoma in situ; Cáncer de mama; Diffusion; Difusión; Ki67; Magnetic resonance imaging; Marcadores pronósticos; p53; Perfusion; Perfusión; Prognostic markers; Radiology; Recidiva; Recurrence; Resonancia magnética; Triple-negative tumors; Tumores triple negativo; Prognostic markers; Resonancia magnética; Recurrence; Carcinoma in situ; Tumores triple negativo; Perfusión; Breast cancer; Triple-negative tumors; p53; Magnetic resonance imaging; Perfusion; Recidiva; Cáncer de mama; Difusión; Diffusion; Ki67; Marcadores pronósticos
• ISSN: 2173-5107; 2173-5107
• DOI: 10.1016/j.rxeng.2016.07.003

Abstract Objectives To analyze what factors in magnetic resonance imaging (MRI) and histological study of triple-negative breast cancers are related to tumor recurrence and to shorter disease-free survival. To analyze survival and recurrence in function of the presence of an in situ component. Material and methods This was a retrospective study of MRI staging examinations in 122 women with triple-negative breast cancer done from 2007 through 2014. In the MRI, we evaluated morphological variables (size, margins, morphology, internal signal in T2-weighted sequences) and dynamic variables (perfusion and diffusion). In the histological study, we evaluated Ki67, p53, CK5/6, nuclear grade, and Scarff–Bloom grade, as well as the presence of an in situ component and tumor grade (high grade or not high grade). We compared the variables between patients with tumor recurrence and those without, and we conducted a survival analysis. Results Non-nodular enhancement was more common in patients with tumor recurrence ( p = 0.038) and was associated with shorter disease-free survival ( p = 0.023). Neither diffusion restriction ( p = 0.079) nor Ki67 ( p = 0.052) was associated with a worse prognosis. An in situ component was detected in 44% of triple-negative tumors, and a greater proportion of patients in the group with tumor recurrence had an in situ component; however, the presence of an in situ component was not associated with shorter survival ( p = 0.185). Conclusion Non-nodular enhancement was associated with a worse prognosis. Diffusion restriction, Ki67, and the presence of an in situ component were not associated with shorter disease-free survival.